DE60012183D1 - USE OF A MACROLIDE COMPOUND FOR PRODUCING A MEDICINE FOR TREATING BRAIN DAMAGE DUE TO ISCHEMIA OR BLEEDING - Google Patents

USE OF A MACROLIDE COMPOUND FOR PRODUCING A MEDICINE FOR TREATING BRAIN DAMAGE DUE TO ISCHEMIA OR BLEEDING

Info

Publication number
DE60012183D1
DE60012183D1 DE60012183T DE60012183T DE60012183D1 DE 60012183 D1 DE60012183 D1 DE 60012183D1 DE 60012183 T DE60012183 T DE 60012183T DE 60012183 T DE60012183 T DE 60012183T DE 60012183 D1 DE60012183 D1 DE 60012183D1
Authority
DE
Germany
Prior art keywords
ischemia
bleeding
medicine
producing
damage due
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60012183T
Other languages
German (de)
Other versions
DE60012183T2 (en
Inventor
Paul Alexander Jones
John Sharkey
John Shearer Kelly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE60012183D1 publication Critical patent/DE60012183D1/en
Publication of DE60012183T2 publication Critical patent/DE60012183T2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Abstract

Macrolide compound, such as a tacrolimus analogue is provided for use as a neuroprotective agent, particularly, for preventing or treating acute or chronic cerebral neurodegenerative diseases.
DE2000612183 1999-07-21 2000-07-19 USE OF A MACROLIDE COMPOUND FOR PRODUCING A MEDICINE FOR TREATING BRAIN DAMAGE DUE TO ISCHEMIA OR BLEEDING Expired - Fee Related DE60012183T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9917158 1999-07-21
GBGB9917158.9A GB9917158D0 (en) 1999-07-21 1999-07-21 New use
PCT/GB2000/002788 WO2001005385A2 (en) 1999-07-21 2000-07-19 New use of a macrolide compound for treating neurodegenerative disorders

Publications (2)

Publication Number Publication Date
DE60012183D1 true DE60012183D1 (en) 2004-08-19
DE60012183T2 DE60012183T2 (en) 2004-11-18

Family

ID=10857695

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2000612183 Expired - Fee Related DE60012183T2 (en) 1999-07-21 2000-07-19 USE OF A MACROLIDE COMPOUND FOR PRODUCING A MEDICINE FOR TREATING BRAIN DAMAGE DUE TO ISCHEMIA OR BLEEDING

Country Status (15)

Country Link
US (1) US20060287353A1 (en)
EP (1) EP1196170B1 (en)
JP (1) JP2003504396A (en)
KR (1) KR100508623B1 (en)
CN (1) CN1200710C (en)
AT (1) ATE270888T1 (en)
AU (1) AU6003900A (en)
CA (1) CA2379140A1 (en)
DE (1) DE60012183T2 (en)
DK (1) DK1196170T3 (en)
ES (1) ES2220492T3 (en)
GB (1) GB9917158D0 (en)
HK (1) HK1047704B (en)
PT (1) PT1196170E (en)
WO (1) WO2001005385A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035411A1 (en) * 2000-12-29 2004-05-26 Fujisawa Pharmaceutical Co USE OF A TACROLIMUS DERIVATIVE TO MANUFACTURE A NEUROTROPHIC AGENT, COMPOSITIONS AND MANUFACTURING ITEMS OR KITS THAT UNDERSTAND IT, METHOD FOR MANUFACTURING AN AGENT THAT UNDERSTANDS AND FABRICS AND GRAINTS WITH A NERVOUS CELL TREATED WITH THIS COMPOSITE
AU2003901023A0 (en) * 2003-03-04 2003-03-20 Fujisawa Pharmaceutical Co., Ltd. New use
JP2007518692A (en) * 2004-01-20 2007-07-12 アステラス製薬株式会社 How to treat erectile dysfunction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB8728820D0 (en) * 1987-12-09 1988-01-27 Fisons Plc Compounds
GR1001225B (en) * 1989-09-14 1993-06-30 Fisons Plc Novel macrocyclic compositions and new application method thereof
GB9202196D0 (en) * 1992-02-01 1992-03-18 Fisons Plc Method of treatment
GB9218027D0 (en) * 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
GB9227055D0 (en) * 1992-12-29 1993-02-24 Fujisawa Pharmaceutical Co New use

Also Published As

Publication number Publication date
KR20020060148A (en) 2002-07-16
HK1047704B (en) 2005-12-16
AU6003900A (en) 2001-02-05
CN1361691A (en) 2002-07-31
EP1196170B1 (en) 2004-07-14
DE60012183T2 (en) 2004-11-18
PT1196170E (en) 2004-10-29
KR100508623B1 (en) 2005-08-17
ES2220492T3 (en) 2004-12-16
JP2003504396A (en) 2003-02-04
EP1196170A2 (en) 2002-04-17
CA2379140A1 (en) 2001-01-25
US20060287353A1 (en) 2006-12-21
WO2001005385A2 (en) 2001-01-25
DK1196170T3 (en) 2004-08-30
ATE270888T1 (en) 2004-07-15
WO2001005385A3 (en) 2001-08-02
GB9917158D0 (en) 1999-09-22
CN1200710C (en) 2005-05-11
HK1047704A1 (en) 2003-03-07

Similar Documents

Publication Publication Date Title
ATE253932T1 (en) USE OF ERYTHROPOIETIN OR ERYTHROPOIETIN DERIVATIVES FOR THE TREATMENT OF CEREBRAL ISCHEMIA
BR0309964A (en) Anticonvulsive Substituted Sulfamoto Derivatives
DE69736183D1 (en) USE OF TOPIRAMATE OR DERIVATIVES THEREOF FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING MAN-DEPRESSIVE BIPOLAR DISORDER
ES2176600T3 (en) DERIVATIVE OF PROPIOFENONE AND PROCEDURES FOR PREPARATION.
BR0209821A (en) Compounds, process for the manufacture of such compounds, pharmaceutical compositions comprising them, process for the treatment and / or prophylaxis of diseases and use of the compounds
BR0010555A (en) Neuraminidase Inhibitors
AR023388A1 (en) AP2 INHIBITORS OF BIFENILOS CONTAINING HETEROCICLIC COMPOUNDS AND TREATMENT METHOD
DK1156798T3 (en) Felbamate-derived compounds
BR0315158A (en) Pyrazole Compounds for the Treatment of Neurodegenative Disorders
CO2021015624A2 (en) Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof and methods of treatment with said compounds
DE60026152D1 (en) USE OF STEARIDONIC ACID FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATMENT OR PREVENTION OF CANCER
AR007021A1 (en) DERIVATIVES OF 3-DESCLADINOSA-2,3-ANHIDROERITROMICINA, PROCEDURES FOR ITS PREPARATION, COMPOUNDS FOR ITS EXCLUSIVE USE IN SUCH PROCEDURES AND PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION TO TREAT BACTERIAL INFECTIONS AND THE USE OF THESE COMPUTERS
DE69829202D1 (en) USE OF MIRTAZAPINE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF SLEEP APNOES
BR0309753A (en) Process for the preparation of 6-alkylidene penem derivatives
ATE246518T1 (en) EGR-1 FOR PRODUCING A MEDICATION FOR THE TREATMENT OF WOUNDS
BRPI0410654A (en) compound, pharmaceutical composition, use of a compound, method for treating a disorder of a patient, and process for the preparation of a compound
DE60012183D1 (en) USE OF A MACROLIDE COMPOUND FOR PRODUCING A MEDICINE FOR TREATING BRAIN DAMAGE DUE TO ISCHEMIA OR BLEEDING
BRPI0512951A (en) compounds, process for their manufacture, pharmaceutical compositions containing them, use and method for treating and / or preventing diseases that are modulated by ppar (delta) and / or ppar (alpha) agonists
BRPI0414139A (en) methods and compositions for treating herpes infections
ATE252383T1 (en) USE OF 2-METHYL-THIAZOLIDINE-2,4-DICARBONIC ACID AND/OR ITS PHYSIOLOGICALLY TOLERABLE SALTS FOR THE PRODUCTION OF A MEDICATION FOR THE TREATMENT OF CANCER DISEASES
ATE206052T1 (en) USE OF SPHINGOSINE-1-PHOSPHATE, SPHINGOSINE-1-PHOSPHATE DERIVATIVES AND/OR MIXTURES THEREOF FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASES
BR0211121A (en) Compound, methods for treating or preventing disease and for making a compound, intermediate, and use of a compound or salt
DE602004030661D1 (en) USE OF KAHALALIDE COMPOUNDS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF PSORIASIS
DE60034110D1 (en) USE OF 4-AMINOPYRIDINE FOR THE TREATMENT OF PERIPHERAL NEUROPATHIES
ATE516038T1 (en) METAL CLUSTER NANOCOMPOINTS FOR THE TREATMENT OF TUMOR DISEASES

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ASTELLAS PHARMA INC., TOKIO/TOKYO, JP

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee